Dapagliflozin
Contents
Description
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption. While primarily indicated for diabetes, it has been studied in renal glycosuria as it targets the same SGLT2 pathway affected in this rare condition. The drug provides insight into glucose handling mechanisms in the kidney.
Indications & Therapeutic Use
Type 2 diabetes mellitus, heart failure, chronic kidney disease, renal glycosuria (investigational)
Linked Diseases:
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Dapagliflozin — GNH India
194 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Dapagliflozin |
| Brands | 1 brand available |
| Active Ingredient | Dapagliflozin |
| Drug Class | Type 2 diabetes mellitus |
| Manufacturer | AstraZeneca |
| Dosage Forms | Tablets 5mg, 10mg |
| Medical Code | A10BK01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01032629 |
| Countries | 9 countries |